Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

van der Heijde, Désirée; Deodhar, Atul; Cheng‐Chung Wei, James; Drescher, Edit; Fleishaker, Dona; Hendrikx, Thijs; Li, David; Menon, Sujatha; S. Kanik, Keith

doi:10.1136/annrheumdis-2016-210322

Public

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

Published in Annals of the Rheumatic Diseases • Jan 27, 2017

Authors:

Désirée van der Heijde

Atul Deodhar

James Cheng‐Chung Wei

Abstract

OBJECTIVES: To compare efficacy and safety of various doses of tofacitinib, an oral Janus kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic axial spondyloarthritis). METHODS: In this 16-week (12-week treatment, 4-week washout), phase II, multicentre, dos...

Subject

Medicine

Tofacitinib

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!